Covalent Data, Inc. announced an agreement that provides JDRF with the ability to track and analyze the resultant output of grant awards to academic researchers. JDRF has helped direct more than $2 billion in research funding since its inception.
Category: Research
This is an important study because really it’s the first to show a defined effect between the development of the microbiome in infancy and the diagnosis of type 1 diabetes. It opens doors to further questions. What I think will come out of this are targeted, prophylactic treatments rather than something that’s meant to cure disease. Scientists need to dig further into what are the important species that are protective in these children.
The study could have important implications for identifying the disease at a very early stage, delaying its onset or even preventing it altogether. Dr. Julia Greenstein, vice president of discovery research at JDRF, which helped fund the study, says that the work is very preliminary, but points toward strategies for prevention that haven’t yet been explored.
Faustman says that her work has raised the ire of some scientists and organizations for two reasons: It runs counter to the prevailing research emphasis to either prevent type 1 diabetes, or reverse it in people who have been recently diagnosed with diabetes and, at the time, ran into a stiff political headwind from embryonic stem cell researchers.
The Diabetes Research Institute (DRI), a Center of Excellence at the University of Miami Miller School of Medicine, announced today that the first…
Sanofi and the Google life sciences team announced that they are collaborating to improve care and outcomes for people with type 1 and type 2 diabetes. The collaboration will pair Sanofi's leadership in diabetes treatments and devices with Google's expertise in analytics, miniaturized electronics and low power chip design.
Is the best way to beat type 1 diabetes to simply stop it before it starts? That’s a question being tackled in new clinical trial that proposes to prevent diabetes in those prone to developing it. “Often times, the best answer is the simple answer,” says Ezio Bonifacio, Ph.D., from the Center for Regenerative Therapies, in Dresden, who led a team of researchers to develop a vaccine to prevent type 1 diabetes. The vaccine has ended up being insulin itself.
The penny-sized patch is embedded with more than one hundred tiny needles, each about the width and length of an eyelash. Those needles in turn are loaded with microscopic storage units containing insulin and glucose-sensing enzymes that trigger a release of insulin when blood sugar levels go past a certain level.
While the drug I worked on at UVA did not prevent or reverse the onset of diabetes, I have continued to study what initiates the development of Type 1 diabetes and how we might be able to stop it. Fueled by my desire to help Katherine, I am working with a team of other scientists from around the world to determine whether or not viruses might play a role in Type 1 diabetes development.
Both type 1 and type 2 are on the rise: since 1985 the number of people with diabetes worldwide has increased ten-fold, from 35 million to 371 million; and it’s projected to double again over the next two decades.